| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | CFO, Cbo | President, CFO, Cbo & Sec'y +3 more
1 company
Benjamin L Palleiko is Chief Executive Officer at KALV. Benjamin L Palleiko's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $12.5M at current prices.
Our model assigns Benjamin L Palleiko a below-average insider score of 46/100, based on 27 past trades. Over a 12-month horizon, 15.8% of those trades were profitable, with an average 12-month return of -34.7%.
The KALV filings lean toward selling, a net 330,210 shares.
Benjamin L Palleiko has 46 Form 4 filings on record from November 2016 to April 2026, all as Chief Executive Officer at KalVista Pharmaceuticals (KALV), 2016–2026.
The 88 reported transactions were 35 open-market sales, 30 option exercises, 19 option or other derivative awards and 4 stock awards.
Counted by filing, the open-market trades come to no purchases and 31 sales worth about $5.0M.
The largest open-market sale was 29,642 shares of KALV at an average $33.59 on February 23, 2021, about $996K.
None of the 25 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | KALV Kalvista Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE | 9,550 | $20.22 | $193,065.67 | -2.0% | - | - | |
| Dec 8, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE | 7,294 | $16.51 | $120,423.94 | -1.7% | +2.6% | - | |
| Nov 24, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE | 10,940 | $13.45 | $147,153.94 | -2.6% | +16.5% | - | |
| Nov 18, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE | 4,466 | $14.48 | $64,665.00 | -1.1% | +5.0% | - | |
| Nov 12, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE | 3,328 | $11.55 | $38,438.40 | -0.8% | +12.5% | - | |
| Sep 8, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE | 7,294 | $15.84 | $115,536.96 | -1.8% | +5.6% | - | |
| Aug 22, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE | 10,940 | $13.22 | $144,657.43 | -2.8% | -2.9% | - | |
| Aug 18, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE | 4,409 | $13.19 | $58,141.48 | -1.2% | +11.4% | - | |
| Jul 9, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Executive Officer | Sell | 32,979 | $15.69 | $517,522.96 | -8.2% | -31.7% | - | |
| Jun 9, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE | 7,169 | $14.50 | $103,950.50 | -2.2% | +8.1% | +82.9% |